NCT07790562
A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions
StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Study completion pushed from Nov 1, 2026 to Jan 2027
- Site details revised
- Notable Eligibility criteria expanded, about 31 words
- Primary completion date changed from estimate of Sep 15, 2026 to Sep 29, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Pharmacokinetic parameter of total iron in serum: maximum observed plasma concentration (Cmax)
Timeframe: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
Pharmacokinetic parameter of total iron in serum: area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)
Timeframe: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
Pharmacokinetic parameter of transferrin bound iron in serum: Cmax
Timeframe: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
Pharmacokinetic parameter of transferrin bound iron in serum: AUC0-t
Timeframe: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
Secondary (1)
Adverse Events (AEs) and Serious Adverse Events (SAE)
Arms and interventions
Test product-Ferric Derisomaltose Injection provided by Sichuan Huiyu Pharmaceutical Co., Ltd.Experimental
Reference product-held by Pharmacosmos A/SActive comparator
Drugs: Ferric Derisomaltose Injection, Ferric Derisomaltose Injection [MonoFer®]
Sites
1 site in 1 country
- Hopeshine-Minsheng Hospital of XinzhengZhengzhou, China